Mosaic ImmunoEngineering Inc. (CPMV)
Mosaic ImmunoEngineering Inc. is an early-stage biotechnology firm dedicated to the advancement and commercialization of an immunomodulatory platform technology. This innovative platform aims to provide therapeutic solutions for cancer and infectious diseases in both human and animal health. The company's core product is MIE-101, a nanoparticle-based treatment sourced from the cowpea mosaic virus, which has demonstrated non-infectious characteristics in mice, dogs, and humans. Headquartered in Novato, California, the company commenced operations in 2020.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
Mosaic ImmunoEngineering Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 7.24M shares outstanding
USMosaic ImmunoEngineering Inc. is an early-stage biotechnology firm dedicated to the advancement and commercialization of an immunomodulatory platform technology. This innovative platform aims to provide therapeutic solutions for cancer and infectious diseases in both human and animal health.
The company's core product is MIE-101, a nanoparticle-based treatment sourced from the cowpea mosaic virus, which has demonstrated non-infectious characteristics in mice, dogs, and humans. Headquartered in Novato, California, the company commenced operations in 2020.
Leadership
Carlton M. Johnson, Jr.
Director
Clifford L. Flowers
Chief Financial Officer/Secretary
Gloria H. Felcyn
Director
Steven W. King
Chairman of the Board, President, CFO & CEO
Employees
2
Country
US
Sector
Healthcare
Website
mosaicie.com
based on 7.24M shares outstanding
US30d Avg
4.41K
60d Avg
2.60K
90d Avg
3.23K